China Fund News Reporter Lu Yu
Baili Tianheng, a leading innovative drug whose share price has hit record highs recently, has reported that it plans to prepare for a Hong Kong stock IPO of no more than US$500 million.
In response to this, Baili Tianheng responded quickly on the evening of May 13 that the company was discussing with relevant intermediaries on the company's issuance of H shares and listing on the main board of the Hong Kong Stock Exchange. As of now, relevant matters are still under review, and the specific details of the issuance of H shares have not yet been determined.
html On May 13, Baili Tianheng's stock price once again hit a record high, and finally closed at 186.16 yuan, a decrease of 4.1%; the market value was 74.65 billion yuan.
is discussing the Hong Kong stock IPO.
The specific details have not yet been determined.
Regarding the market rumors that the company plans to prepare for a Hong Kong IPO of no more than 500 million US dollars, Baili Tianheng announced on the evening of May 13 that in recent years, Baili Tianheng’s international business It continues to expand, its international layout continues to deepen, and global cooperation has made significant progress. The company has paid attention to the relevant public opinions in the market, and hereby explains the relevant matters as follows:
In order to further assist the development of the company's international business, make better use of domestic and overseas financing platforms, consolidate the company's rapidly growing capital reserves, and support the company's many innovative products in Europe, The global development of the United States, Japan and other international markets has vigorously promoted the implementation of the company's strategy of growing into a multinational pharmaceutical company (mnc) with global leading advantages in the field of oncology drugs. The company is working with relevant intermediaries to issue H shares of the company and sell them in Hong Kong The company will fully consider the interests of existing shareholders, the company's value reflection and the domestic and overseas capital market conditions in its research and judgment. As of now, relevant matters are still under review, and the specific details of the issuance of H shares have not yet been determined.
Bailey Tianheng said that according to the relevant regulations for A-share listed companies to issue H shares and list them in Hong Kong, this matter needs to be submitted to the company’s board of directors and shareholders’ meeting for review, and will be reviewed by the Hong Kong Stock Exchange and filed with the China Securities Regulatory Commission. Whether it can be There are significant uncertainties in passing the review and review/filing process and final implementation.
has surged as much as 97.75% in the past month.
In the past month, Baili Tianheng’s stock price has risen by as much as 97.75%, and its stock price has hit record highs recently.
wind data shows that last week, a total of 217 A-share listed companies were surveyed by institutional investors during the week, which was a significant increase compared with the pre-holiday data. Among them, the target with the largest number of research institutions is Baili Tianheng. The company received a total of 220 research institutions during the week.
Due to the advanced progress of product development and good potential efficacy data, in December 2023, the multinational pharmaceutical giant Bristol-Myers Squibb made a down payment of US$800 million, near-term contingent payments of up to US$500 million, and a potential milestone payment of US$7.1 billion. , with a total transaction amount of up to US$8.4 billion, it reached a cooperation with Bailey Tianheng and obtained the overseas development and commercialization rights of bl-b01d1.
In March 2024, Bailey Tianheng received a down payment of US$800 million. Affected by this, in the first quarter of 2024, Baili Tianheng's revenue reached 5.462 billion yuan, a year-on-year increase of 4325%; net profit was 5.005 billion yuan, a year-on-year increase of 3100.16%, making it profitable for the first time.
Editor: Joey
Copyright Statement
"China Fund News" owns the copyright to the original content published on this platform. Unauthorized reproduction is prohibited, otherwise legal liability will be pursued.
